Literature DB >> 8681900

Systematic testing of medical intractability for carbamazepine, phenytoin, and phenobarbital or primidone in monotherapy for patients considered for epilepsy surgery.

G Hermanns1, S Noachtar, I Tuxhorn, H Holthausen, A Ebner, P Wolf.   

Abstract

PURPOSE: To assess medical intractability in patients considered for restrictive epilepsy surgery.
METHODS: Seventy-four patients received single drug treatment with carbamazepine (CBZ), phenytoin (PHT), and either phenobarbital (PB) or primidone (PRM). Medical intractability was established if seizure control was not obtained despite maximum tolerable doses of the drug. In all, 120 single drug treatments were administered with the drugs that has not been administered at maximal doses in monotherapy before the study.
RESULTS: Complete seizure control was not achieved in any patient. However, 7 patients (9.5%) had significant seizure reduction of at least 80%. In 4 patients, only the third antiepileptic drug (AED) proved effective.
CONCLUSION: The poor result of AED monotherapy in our patients may be attributed to the patients' long-standing chronic epilepsies and high seizure frequencies. Our findings suggest that despite the failure of one or two major AEDs in controlling seizures completely, further single drug treatment may still improve the quality of life in some patients who are candidates for epilepsy surgery.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8681900     DOI: 10.1111/j.1528-1157.1996.tb00632.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  2 in total

1.  Long term effects of refractory temporal lobe epilepsy on cognitive abilities: a cross sectional study.

Authors:  H Jokeit; A Ebner
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-07       Impact factor: 10.154

Review 2.  Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation.

Authors:  E Perucca; O Dulac; S Shorvon; T Tomson
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.